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INTRODUCTION
Sexual side effects are a common and bothersome reaction 
to most available antidepressants, frequently leading to cessa-
tion of treatment, with a rate of 10-30% for serotonin reuptake 
inhibitors (SSRIs).
1 One of the approaches for antidepressant-
induced sexual dysfunction is augmentation of another agent 
to ongoing treatment. Mirtazapine has a unique tolerability pro-
file, since the specific postsynaptic 5-HT2 and 5-HT3 receptor 
blockade of mirtazapine provides early antidepressant effects 
without causing unwanted serotonin-related side effects, par-
ticularly sexual dysfunction;
2 in contrast, these features may re-
lieve sexual function disorders.
Therefore, the aim of this study was to identify sexual dys-
function in patients with major depressive disorder under the 
mirtazapine-augmented SSRI treatment.
METHODS 
This is a retrospective observational study in which the me-
dical records of 20 heterosexual outpatients (11 males and 9 
females), under the mirtazapine augmented SSRI treatment 
for their major depressive disorder who had been selected 
among the patients that had developed sexual dysfunction to 
previous treatment, in monotherapy, with SSRI for least for six 
weeks. The mean age was 27.7±5.8 years (range=20-46 years). 
Twelve of the patients graduated from high school and univer-
sity, five from elementary school and three from primary school. 
In regard to socioeconomical status, ten had low income level, 
whereas six had moderate and four had high. The procedures 
followed were in accordance with the Helsinki Declaration of 
1975, as revised in 1983, with written informed consents and 
ethics approval.
To exclude the organic sexual dysfunctions, biochemical eva-
luations were performed. Exclusion criteria were the followings; 
being over 45 years old, a concurrent medical illness affecting 
sexual function, the existence of polypharmacy with another 
psychotropic drug (except for benzodiazepines), previous or cur-
rent alcohol and substance abuse or dependence, the presence of 
any endocrinological state, treatment with any hormones, and 
a history of pre-existing sexual dysfunction. 
Antidepressant drugs that the patients had received were es-
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Table 1. HAM-D, ASEX and CGI-I scale scores during treatment*
Weeks HAM-D ASEX CGI-I
0 16.8±4.40. 23.3±4.2.0 -
4 11.2±2.6** 17.0±3.3** 3.3±1.1
8 009.4±2.2*** 011.8±2.4*** 00.2.0±1.2***
*used paired t-test, **p<0.05, ***p<0.01 (statistical significance of ch-
ange according to baseline). HAM-D: Hamilton Depression Rating, 
ASEX: Arizona Sexual Experience Scale, CGI-I: Clinical Global 
Impression-Improvement
citalopram (n=5, 40-60 mg/day), sertraline (n=4, 100-200 mg/
day), clomipramine (n=3, 20-60 mg/day), fluvoxamine (n=3, 
100-300 mg/day), paroxetine (n=3, 20-60 mg/day) and citalo-
pram (n=2, 20-60 mg/day). These antidepressants were main-
tained and mirtazapine (15-45 mg/day) was added. No concom-
itant psychotropic medication except for benzodiazepines was 
permitted. 
They were screened by using Hamilton Depression Rating 
(HAM-D)
3, Clinical Global Impression-Improvement (CGI-I) 
and Arizona Sexual Experience Scale (ASEX)
4 scales at week 4, 
and 8. 
Data were statistically analyzed using SPSS Microsoft Win-
dows 9.05. Paired t-test was used. Results are given in the text as 
means±SD, with a p value of <0.05.
RESULTS
Prior to adding mirtazapine, the most frequently experienced 
sexual dysfunctions associated SSRIs were decreased libido 
(55%; four patients receiving paroxetine, three patients receiv-
ing clomipramine, two patients receiving fluvoxamine, and two 
patients taking sertraline), followed by erectile dysfunction 
(36.4% of the males; two patients receiving paroxetine, one pa-
tient receiving clomipramine, and one patient receiving sertra-
line), delay of orgasm or ejaculation (25%; two patients receiv-
ing clomipramine, two patients receiving paroxetine, and one 
patient receiving citalopram), anorgasmia or no ejaculation (10%; 
one patient receiving paroxetine, and one patient receiving cita-
lopram), and lubrication disorder in one patient receiving clo-
mipramine (11.1% of the females). 
Of the 20 patients participating in the augmentation, only one 
did not complete the study because of oversedation and incr-
eased appetite. The mean HAM-D score was 16.8±4.4 at base-
line, 11.2±2.4 at week 4, and 9.4±2.2 at week 8. Paired t-tests 
revealed a significant difference on HAM-D scores between ba-
seline and week 4 (p<0.05) or week 8 (p<0.01). The mean ASEX 
score was 23.3±4.2 at baseline, 17.0±3.3 at week 4, and 11.8± 
2.6 at week 8. There was a significant difference between base-
line and week 4 (p<0.05) or week 8 (p<0.01) in scores on the ASEX 
(Table 1). Responders and nonresponders did not differ in sex, 
age and HAM-D scores at baseline (p>0.05). 
There was no correlation between decrease in HAM-D scores 
and that in ASEX scores (r=0.07, p>0.05). At the end of the study, 
seven patients (36.8%) were rated as very much improved (CGI-
I=1), and six patients (31.6%) were rated as much improved 
(CGI-I=2). Thus, 68.4% of the patients were responders. At the 
end point, the majority of the patients were taking low doses of 
mirtazapine (15 mg per day in ten patients, 30 mg per day in five 
patients and 45 mg per day in four patients).
The combination of SSRI-mirtazapine was generally well-to-
lerated. Ten patients complained of side effects. The most com-
mon side effects were sedation (6 patients), weight gain up to 3 
kg (2 patients). 
DISCUSSION
This retrospective study showed that in patients reporting 
sexual dysfunction associated with SSRIs, the addition of mir-
tazapine provided considerable improvement in sexual function. 
A variety of strategies have been reported in the management 
of SSRI-induced sexual dysfunction, including dose reduction, 
drug holidays, substitution of another antidepressant drug, and 
various augmentation strategies, including use of sildenafil ci-
trate, buspirone, and others.
5,6  
There are limited studies regarding mirtazapine use in pa-
tients with antidepressant-induced sexual dysfunction. Kout-
ouvidis et al.
7 and Gelenberg et al.
8 reported the patients who 
had experienced sexual dysfunction while taking an SSRI were 
switched to mirtazapine and found that majority of the patients 
returned to normal sexual functioning. A mirtazapine augmen-
tation study of patients with SSRI-induced sexual dysfunction 
which also had comparison groups of olanzapine, yohimbine, 
and placebo addition, showed that there was statistically signi-
ficant improvement on most measures for the overall group of 
patients.
9 But that study included only pre-menopausal patients 
with orgasmic dysfunction. Recently, Ozmenler et al.
10 evaluat-
ed the effect of mirtazapine augmentation in patients with sex-
ual dysfunction induced by current SSRI treatment and con-
cluded that mirtazapine augmentation might be a good choice 
for the treatment of SSRI-induced sexual dysfunction. To our 
knowledge, however, the data reported in the present study 
when excluded for Ozmenler et al.’s study represents the first as-
sessment of the efficacy of mirtazapine augmentation in both 
male and female patients with a variety of sexual dysfunctions. 
Mirtazapine, an α2 antagonist, is also a unique antidepressant that 
enhances noradrenergic and 5-HT1A-activated neurotransmis-
sion; it does not inhibit norepinephrine or serotonin reuptake. 
In addition, mirtazapine causes blockade of postsynaptic 5-HT2 
and 5-HT3 receptors, which should spare sexual function. We 
suggest that the postsynaptic 5-HT antagonistic effects of mir-
tazapine, combined with its presynaptic α2-adrenoreceptor blo-M Atmaca et al. 
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ckage are the mechanism of action that reverses the sexual dys-
function induced by SSRIs. On the other hand, since adverse 
sexual effects related to SSRI treatment are believed to be me-
diated through 5-HT2 stimulation, possible relief of symptoms 
may result from blocking these receptors by mirtazapine.
11
It is likely that mirtazapine activates noradrenaline neuronal 
activity and correlates noradrenaline and dopamine by inhib-
iting α2-adrenoceptor in the medial prefrontal cortex and oc-
cipital cortex. Dopamine, released in several major integrative 
areas before and/or during copulation, facilitates sexual motiva-
tion, motor performance, and genital reflexes.
12 These different 
properties of mirtazapine may account for its usefulness in an-
tidepressant-induced sexual dysfunctions caused by other an-
tidepressants. 
The findings should be subject to some limitations. Firstly, 
the retrospective design and sample size were major limitations. 
Furthermore, no control group was used. In fact, in the present 
study, no correlation was found between decrease in HAM-D 
scores and that in ASEX scores. Therefore, it appears the impro-
vements in sexual functions to be independent from decrease 
in depressive state. 
In conclusion, the results of our study reported herein dem-
onstrate that mirtazapine may be beneficial in patients with 
SSRI-induced sexual dysfunction. 
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